Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FCC continues to approve their leases as recently as today at both 28 and 39 GHz. When we get clarity on FCC investigation, we will move one way or the other! Bullish! If outcome is sympathetic to STRP, I have to think market cap at least rivals XO Communication deal of 1.8b. So minimum $150 pps.
Kerrisdale report speaks to mmwave spectrum as if 39ghz is the same as 100 GHz. Time for them to read wireless providers comments to FCC in latest nprm. Everything kerrisdale report claimed to be a low delta chance is now happening. There is no other publicly traded company that provides 5G spectrum exposure.
Divea, so i've spent my morning looking over the resume of Dr. Dhillon as you made me realize that I was actually not comfortable with my knowledge of ARTH's board of directors.
I do not see your perspective on the following:
1) Inovio: President and CEO. Current mkt cap of 483m. Company traded sub $2 when he took over. Traded up to $20 by 2005.
2) MDS Capital Corp. (Lumira Capital Corp.): VP
3) Cardiome Pharma Corp: Consultant. Company went on to trade at market cap of almost $1.8b by 2005.
4) Protox Therapeutics: Founding board member. Company tripled in first 2 years. He left after securing financing in 2010. Company sidelined until 2014 and ultimately declined.
5) BC Advantage Funds: Mentor/Director.
Regarding the following OTC stocks you mentioned:
1) Stevia First. This is essentially a dietary start-up focussing on a new form of artificial sweetener. This is a far cry from the MIT licensed technology and potential behind AC5. Were you investing in Stevia? If so, I would love to hear why...
2) OncoSec Medical, INC. This company is developing DNA-based immunotherapy to treat tumors/cancers. Dhillon served as the Chairman of the Board of Directors, yes. He was brought on after the stock declined from above $30 to sub $4. Brought in to help realign the corporate mission perhaps? He was brought in as the stock was collapsing.
Lastly,
There are two red flags that I have come across with ARCH. 1, the company went public via reverse merger and 2, the 2013 pump article.
Here is what I will say. 1, Dr. Norchi was interviewed on the reverse merger. His answer basically states that it was 2008-2009 where the financial crisis had all but eliminated access to capital. Reverse Merger was the cheapest way to compete. 2, There was never any connection made between ARCH and the stock promoting publication. It is assumed an equity owner promoted this company themselves.
One additional point, ARCH refinanced their outstanding debt to pay it down 1 year earlier at better terms. What company would do that other than one focused on efficient capital allocation.
I agree...I love the incentive to do more dd. On that note, for the third time, I went through Dr. Dhillon's resume and I suggest you all do the same. He was brought on as chairman of the board for a couple otc company's that were looking for new life...yes. However, it's more important to look at his accomplishments as well as the respective stock performances of the other companies he's been a leader at.
I guess my question to you would be what specifically about ac5 can you call into question. I don't want to discount a company simply bc you list a few other companies that have failed. Further, what specifically re arch's mgmt can we question? I understand why they did a reverse merger...it was 2008 and we thought the world was going to end.
Ah perfect. 24%. Thanks.
Do you happen to know how much? I've seen this claim but I have never seen it clarified/quantified.
To be clear, I am also heavily invested here...so just trying to improve dd.
What exactly does he have financially invested?
At the end of the day, there remain over 17 million shares on the other end of the outstanding warrants I believe. That means that absent institutional demand or closer realization of revenue, we will remain on the sidelines. Bullish.
Yes, those appear to all be tied to previous private placements?
Good question...trying to find details
They already stated this...it just means they have the ability to sell a predetermined amount over time
That's the jan 2016 list...doesn't look like 2017 presenters are out yet
11% on 65k shares...someone wants them now
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
They finally changed their sec filing from an auto parts supplier to surgical and medical instruments and apparatus. I must say, this was the only red flag I found since I started investing last winter...good to see the co reduce debt and get further organized!
While reverse mergers are usually a red flag, I continue to be pleasantly impressed with progress here.
Looks like co is initiating an early repayment of a 1m usd loan.
8k out
One's expectations for this afternoon should be extremely low. There are dozens of companies sharing the stage offered by this gathering. However, I wouldn't be surprised to see this event help the company gain some much needed attention from the investment community. I am long term bullish and have been invested for quite some time. I find the short term pps swings completely irrelevant so long as we remain between .20 and 1.00. A breakout to either side will suggest that something has changed. Until then, pps reflects speculative sentiment and little more.
Yes, it's great!
And from Keynes: "the market can stay irrational longer than you can stay solvent."
Anything sub 50
This should pressure on retail longs...buy zone down here